Medexus Pharmaceuticals (TSE:MDP) Upgraded to “Strong-Buy” at Leede Financial

Leede Financial upgraded shares of Medexus Pharmaceuticals (TSE:MDP) from a moderate buy rating to a strong-buy rating in a research report sent to investors on Wednesday,Zacks.com reports. Leede Financial also issued estimates for Medexus Pharmaceuticals’ FY2025 earnings at $0.29 EPS, FY2027 earnings at $0.69 EPS and FY2028 earnings at $1.30 EPS.

Other equities research analysts also recently issued reports about the stock. Raymond James upgraded shares of Medexus Pharmaceuticals from an “outperform” rating to a “strong-buy” rating and set a C$4.00 price target for the company in a report on Wednesday, January 8th. Stifel Nicolaus lifted their target price on shares of Medexus Pharmaceuticals from C$4.15 to C$4.50 in a research note on Tuesday, January 14th. Alliance Global Partners raised Medexus Pharmaceuticals to a “strong-buy” rating in a research note on Monday, December 23rd. Finally, Ventum Cap Mkts upgraded Medexus Pharmaceuticals to a “strong-buy” rating in a report on Friday, January 17th. One investment analyst has rated the stock with a buy rating and five have given a strong buy rating to the company. According to MarketBeat.com, Medexus Pharmaceuticals has a consensus rating of “Strong Buy” and an average target price of C$5.58.

Medexus Pharmaceuticals Stock Up 19.0 %

Shares of TSE:MDP opened at C$4.75 on Wednesday. The company has a market capitalization of C$116.52 million, a P/E ratio of 95.00 and a beta of 1.96. Medexus Pharmaceuticals has a 52-week low of C$1.47 and a 52-week high of C$5.56. The stock’s fifty day simple moving average is C$3.14 and its 200-day simple moving average is C$2.69.

Medexus Pharmaceuticals Company Profile

Medexus Pharmaceuticals Inc operates as a specialty pharmaceutical company in Canada and the United States. The company focuses on the therapeutic areas comprising oncology, hematology, rheumatology, auto-immune diseases, allergy, and dermatology. Its primary products are IXINITY, an intravenous recombinant factor IX therapeutic for use in patients 12 years of age or older with hemophilia B; Rasuvo and Metoject, a formulation of methotrexate designed to treat rheumatoid arthritis and other auto-immune diseases; Rupall, a prescription allergy medication; and Gleolan, an optical imaging agent indicated in patients with glioma as an adjunct for the visualization of malignant tissue during surgery.